PD 169316
Based on 28 publication(s) in Google Scholar
PD 169316 is a potent, cell-permeable and selective p38 MAP kinase inhibitor, with IC50 of 89 nM. PD169316 selectively inhibits the kinase activity of the phosphorylated p38 without hindering upstream kinases to phosphorylate p38. PD169316 shows antiviral activity against Enterovirus71. PD169316 shows antiviral activity against Enterovirus71.
For research use only. We do not sell to patients.
- Purity: 99.07%
- CAS No.: 152121-53-4
- Formula: C20H13FN4O2
- Molecular Weight:360.34
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
Publications Citing Use of MedChemExpress (MCE) PD 169316
More- Bioact Mater. 2021 Jul 1:8:109-123. [Abstract]
- Metabolism. 2025 Aug:169:156298. [Abstract]
- Interdiscip Med. 2026 May 18.
- Adv Sci (Weinh). 2025 Sep;12(36):e03722. [Abstract]
- Adv Sci (Weinh). 2025 Aug 4:e03972. [Abstract]
- Cell Rep Med. 2026 Apr 21;7(4):102691. [Abstract]
- Cell Death Differ. 2026 Jan 15. [Abstract]
- Cancer Lett. 2025 Aug 29:633:218010. [Abstract]
- ACS Appl Mater Interfaces. 2021 Feb 3;13(4):5782-5794. [Abstract]
- Brain Behav Immun. 2025 Mar 31:S0889-1591(25)00122-9. [Abstract]
- Br J Pharmacol. 2019 Aug;176(15):2691-2707. [Abstract]
- Genes Dev. 2018 Sep 1;32(17-18):1215-1225. [Abstract]
- Hum Reprod. 2025 Sep 26:deaf174. [Abstract]
- Antioxid Redox Signal. 2023 Mar;38(7-9):480-495. [Abstract]
- Ecotoxicol Environ Saf. 2024 Nov 1:286:117223. [Abstract]
- Ecotoxicol Environ Saf. 2022 May 1;236:113468. [Abstract]
- Int J Mol Sci. 2025 Aug 6;26(15):7624. [Abstract]
- Chem Biol Interact. 2024 Nov 1:403:111253. [Abstract]
- Mol Cell Biochem. 2025 Jun;480(6):3709-3717. [Abstract]
- Oncol Rep. 2017 Dec;38(6):3668-3676. [Abstract]
- J Virol. 2023 Jun 29;97(6):e0028423. [Abstract]
- Int J Med Sci. 2016 Jul 18;13(8):611-9. [Abstract]
- Mol Cell Biol. 2025;45(3):99-115. [Abstract]
- Virology. 2017 Aug:508:150-158. [Abstract]
- Oncol Lett. 2018 Jan;15(1):235-242. [Abstract]
- Oncol Lett. 2017 Nov;14(5):6314-6320. [Abstract]
- bioRxiv. 2025 Feb 2:2025.02.01.636075. [Abstract]
- Chinese Journal of Cell Biology. 2016, 38(7): 770–776
-
WB
-
WB
-
WB
-
WB
Biological Activity
IC50: 89 nM (p38 MAPK)[5]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| RBL-1 | IC50 |
8 μM
Compound: 22
|
Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells
Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells
|
10.1016/0960-894X(95)00189-Z |
PD169316 (10 μM) inhibits TGFβ and Activin A, but not BMP4 signaling in CaOV3 cells. PD169316 (0.2-20 μM) inhibits TGFβ-induced Smad2 nuclear translocation, Smad7 mRNA induction, and reporter gene activity in CaOV3 cells[1]. PD169316 (10 μM) shows a significantly increased rate of proliferation in Nestin knockdown cells, and can rescue the effect of Nestin knockdown on cell viability in the absence of EGF[2]. PD169316 significantly inhibits p38 MAP kinase activity with no significant change in ERK activity in PC12 cells. PD169316 (10 μM) blocks apoptosis induced by trophic factor withdrawal in differentiated PC12 cells[3].PD169316 (10 μM, 30 min) selectively inhibits the kinase activity of the phosphorylated p38 without hindering upstream kinases to phosphorylate p38. Increased phospho p-38 levels in the presence of PD169316 are most likely due to blockade of negative feedback loop of dephosphorylation of p38 MAPK by MAPK phosphatases[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Ishikawa PRB or PRA cells.
-
Concentration:10 μM.
-
Incubation Time:30 min.
-
Result:Did not inhibit MEKK1-induced p38 phosphorylation.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:EV71-challenged suckling mouse model (7-day-old Kunming mice)[5].
-
Dosage:1 mg/kg.
-
Administration:Intramuscular injection every day for 14 consecutive days.
-
Result:Showed antiviral activity.
Chemical Information
-
CAS No. 152121-53-4
-
Appearance Solid
-
Molecular Weight 360.34
-
Formula C20H13FN4O2
-
Color Light yellow to yellow
-
SMILES
FC(C=C1)=CC=C1C2=C(C3=CC=NC=C3)NC(C4=CC=C([N+]([O-])=O)C=C4)=N2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (28)
-
Journal Impact Factor
-
Most Recent
-
Bioact Mater
Nanoporous titanium implant surface promotes osteogenesis by suppressing osteoclastogenesis via integrin β1/FAKpY397/MAPK pathway. [Abstract]2021 Jul 1:8:109-123. PMID: 34541390 -
Metabolism
Chemical discovery of a novel MD2/ADAM17 dual-target inhibitor as a potential therapeutic candidate for saturated fatty acid-induced myocardial inflammatory injury. [Abstract]2025 Aug:169:156298. PMID: 40381836 -
-
Adv Sci (Weinh)
Neutrophil Mobilization Triggers Microglial Functional Change to Exacerbate Cerebral Ischemia-Reperfusion Injury. [Abstract]2025 Sep;12(36):e03722. PMID: 40557450 -
Adv Sci (Weinh)
2025 Aug 4:e03972. PMID: 40755418 -
Cell Rep Med
HE4 drives PD-L1 expression in myeloid cells via IFN-γR-JAK-STAT3 signaling to promote tumor immune evasion. [Abstract]2026 Apr 21;7(4):102691. PMID: 41861828 -
Cell Death Differ
EGFR orchestrates neutrophil activation and NETosis via CEBPβ-dependent PGLYRP1 induction. [Abstract]2026 Jan 15. PMID: 41540251 -
Cancer Lett
Targeting MKK3/c-Myc interaction to overcome osimertinib acquired resistance in EGFR mutant lung cancer. [Abstract]2025 Aug 29:633:218010. PMID: 40886822 -
ACS Appl Mater Interfaces
The Translation from In Vitro Bioactive Ion Concentration Screening to In Vivo Application for Preventing Peri-implantitis. [Abstract]2021 Feb 3;13(4):5782-5794. PMID: 33464812 -
Brain Behav Immun
TLR9 in satellite glial cells promotes paclitaxel-induced neuropathic pain by reducing Kir4.1 transcription through histone methylation activation. [Abstract]2025 Mar 31:S0889-1591(25)00122-9. PMID: 40174869 -
Br J Pharmacol
Blockade of the forward Na+ /Ca2+ exchanger suppresses the growth of glioblastoma cells through Ca2+ -mediated cell death. [Abstract]2019 Aug;176(15):2691-2707. PMID: 31034096 -
Genes Dev
2018 Sep 1;32(17-18):1215-1225. PMID: 30150253 -
Hum Reprod
Increased AIF-1-mediated p38 MAPK phosphorylation in the mid-secretory endometrium impairs endometrial receptivity in women with recurrent implantation failure. [Abstract]2025 Sep 26:deaf174. PMID: 41003697 -
Antioxid Redox Signal
TXNIP exacerbates the senescence and ageing-related dysfunction of β-cells by inducing cell cycle arrest through p38-p16/p21-CDK-Rb pathway. [Abstract]2023 Mar;38(7-9):480-495. PMID: 36070438 -
Ecotoxicol Environ Saf
SKI-606, a Src inhibitor, ameliorates benzene-induced hematotoxicity via blocking ROS/Src kinase-mediated p38 and Akt signaling pathways. [Abstract]2024 Nov 1:286:117223. PMID: 39447291 -
Ecotoxicol Environ Saf
2022 May 1;236:113468. PMID: 35378400 -
Int J Mol Sci
Transcriptional Repression of CCL2 by KCa3.1 K+ Channel Activation and LRRC8A Anion Channel Inhibition in THP-1-Differentiated M2 Macrophages. [Abstract]2025 Aug 6;26(15):7624. PMID: 40806751 -
Chem Biol Interact
Lanostane triterpenoids from Ganoderma calidophilum exhibit potent anti-tumor activity by inhibiting PTP1B. [Abstract]2024 Nov 1:403:111253. PMID: 39341486 -
Mol Cell Biochem
MAPK signaling mediated intestinal inflammation induced by endoplasmic reticulum stress and NOD2. [Abstract]2025 Jun;480(6):3709-3717. PMID: 39806198 -
Oncol Rep
Cisplatin-induced autophagy protects breast cancer cells from apoptosis by regulating yes-associated protein. [Abstract]2017 Dec;38(6):3668-3676. PMID: 29039616
PD 169316 purchased from MedChemExpress. Usage Cited in: Oncol Rep. 2017 Dec;38(6):3668-3676. [Abstract]
Western blot analysis evaluated p-p38, p38, LC3 and quantification of LC3-II in untreated (control), treated with the p38 inhibitor PD169316, cisplatin, and both these agents in MDA-MB-231 cells.
-
J Virol
Critical Role of Viral Protein Hexon in Hypervirulent Fowl Adenovirus Serotype-4-Induced Autophagy by Interaction with BAG3 and Promotion of Viral Replication in LMH Cells. [Abstract]2023 Jun 29;97(6):e0028423. PMID: 37255472 -
Int J Med Sci
NLS-RARα Inhibits the Effects of All-trans Retinoic Acid on NB4 Cells by Interacting with P38α MAPK. [Abstract]2016 Jul 18;13(8):611-9. PMID: 27499693
PD 169316 purchased from MedChemExpress. Usage Cited in: Int J Med Sci. 2016 Jul 18;13(8):611-9. [Abstract]
PD169316 (10 μM) inhibits the effects of all-trans retinoic acid(ATRA) on nuclear localization signal retinoic acid receptor alpha (NLS-RARα)-overexpressed NB4 cells incluing an increase of the expressions of p-p38α, C/EBPβ and CD11b.
-
Mol Cell Biol
Kinase Inhibitor-Induced Cell-Type Specific Vacuole Formation in the Absence of Canonical ATG5-Dependent Autophagy Initiation Pathway. [Abstract]2025;45(3):99-115. PMID: 39895059 -
Virology
2017 Aug:508:150-158. PMID: 28545002 -
Oncol Lett
2018 Jan;15(1):235-242. PMID: 29387217
PD 169316 purchased from MedChemExpress. Usage Cited in: Oncol Lett. 2018 Jan;15(1):235-242. [Abstract]
Cells are treated with 15 and 20 μM Lapatinib for 24 h, the expression of p AKT, AKT, p p38 MAPK, p38 MAPK, p JNK, and JNK are measured by western blotting. Quantification analysis of western blotting, β actin is served as a control. D: 1 DMSO; 2 PD169316; 3 15 μM Lapatinib; 4 PD169316+15 μM Lapatinib).
-
Oncol Lett
Epigallocatechin-3-gallate induces apoptosis in acute promyelocytic leukemia cells via a SHP-1-p38α MAPK-Bax cascade. [Abstract]2017 Nov;14(5):6314-6320. PMID: 29113283 -
bioRxiv
2025 Feb 2:2025.02.01.636075. PMID: 39975412 -
PD 169316 purchased from MedChemExpress. Usage Cited in: Chinese Journal of Cell Biology. 2016, 38(7): 770–776
The protein levels of Bax and Bcl-2 detected by Western blot. PD169316 decreases EGCG-mediated increases in Bax protein expression.
Solvent & Solubility
DMSO : 12.5 mg/mL (34.69 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 1.25 mg/mL (3.47 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 1.25 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 1.25 mg/mL (3.47 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 1.25 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 50% PEG300 50% Saline
Solubility: 5 mg/mL (13.88 mM); Suspended solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (282 KB)
-
SDS (582 KB)
- English - EN (582 KB)
- Français - FR (582 KB)
- Deutsch - DE (582 KB)
- Norwegian - NO (582 KB)
- Español - ES (582 KB)
- Swedish - SV (582 KB)
- Italian - IT (582 KB)
- Korean - KR (582 KB)
- Portuguese - PT (582 KB)
-
Handling Instructions (2659 KB)
References
[1]. Fu Y, et al. The p38 MAPK inhibitor, PD169316, inhibits transforming growth factor beta-induced Smad signaling in human ovarian cancer cells. Biochem Biophys Res Commun. 2003 Oct 17;310(2):391-7. [Content Brief]
[2]. Hu W, et al. Suppression of Nestin reveals a critical role for p38-EGFR pathway in neural progenitor cell proliferation. Oncotarget. 2016 Dec 27;7(52):87052-87063. [Content Brief]
[3]. Kummer JL, et al. Apoptosis induced by withdrawal of trophic factors is mediated by p38 mitogen-activated protein kinase. J Biol Chem. 1997 Aug 15;272(33):20490-4. [Content Brief]
[4]. Khan JA, et al. p38 and p42/44 MAPKs differentially regulate progesterone receptor A and B isoform stabilization. Mol Endocrinol. 2011 Oct;25(10):1710-24. [Content Brief]
[5]. Zhang Z, et al. PD169316, a specific p38 inhibitor, shows antiviral activity against Enterovirus71. Virology. 2017 Aug;508:150-158. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.7752 mL | 13.8758 mL | 27.7516 mL | 69.3789 mL |
| 5 mM | 0.5550 mL | 2.7752 mL | 5.5503 mL | 13.8758 mL | |
| 10 mM | 0.2775 mL | 1.3876 mL | 2.7752 mL | 6.9379 mL | |
| 15 mM | 0.1850 mL | 0.9251 mL | 1.8501 mL | 4.6253 mL | |
| 20 mM | 0.1388 mL | 0.6938 mL | 1.3876 mL | 3.4689 mL | |
| 25 mM | 0.1110 mL | 0.5550 mL | 1.1101 mL | 2.7752 mL | |
| 30 mM | 0.0925 mL | 0.4625 mL | 0.9251 mL | 2.3126 mL |